Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Dana Pizzuti sold 15,089 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.06, for a total value of $664,821.34. Following the completion of the transaction, the insider now owns 27,786 shares […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Matthew K. Fust sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.14, for a total transaction of $2,648,400.00. Following the completion of the sale, the director now directly owns […]
HC Wainwright reaffirmed their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research report released on Tuesday, Benzinga reports. The brokerage currently has a $50.00 price objective on the stock. CRNX has been the topic of a number of other reports. JMP Securities upped their price target on shares of […]
Citigroup assumed coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note published on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $68.00 price objective on the stock. Several other equities research analysts also recently weighed in on CRNX. Oppenheimer increased their price target on Crinetics […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price objective lifted by research analysts at Oppenheimer from $46.00 to $48.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 7.50% from the stock’s previous close. […]